Other
Prospective
0
Pipeline Programs↗
34
Active Trials↗
21
Companies Involved↗
Prospective is an early-stage landscape with 0 programs across 21 companies. The most active players are GSK, Pfizer, Johnson & Johnson.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
215
clinical trials
Completed108 · 50%
Unknown status54 · 25%
Recruiting18 · 8%
Not yet recruiting11 · 5%
Withdrawn10 · 5%
Terminated9 · 4%
Other5 · 2%
Clinical Trials
Trial Activity
215 trials
Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients
Recruiting·—·N/A·NCT04840355·100 enrolled
Prospective RCT Lidocaine & Levobupivacaine on Block Dynamics After Subparaneural Popliteal Sciatic Nerve Block
Recruiting·—·Phase 4·NCT04397484·40 enrolled
A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT03980002·50 enrolled
Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial
Recruiting·—·N/A·NCT06262386·358 enrolled
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT04501523·460 enrolled
Page 1 of 15
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)